Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CEO Sean Duffy sold 17,258 shares of the firm's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $20.68, for a total transaction of $356,895.44. Following the sale, the chief executive officer directly owned 382,594 shares of the company's stock, valued at approximately $7,912,043.92. The trade was a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Omada Health Trading Up 2.8%
OMDA stock traded up $0.58 during trading on Monday, reaching $20.95. The stock had a trading volume of 747,067 shares, compared to its average volume of 1,277,139. The firm has a fifty day moving average price of $21.80 and a 200 day moving average price of $18.68. The company has a market capitalization of $1.28 billion, a P/E ratio of 419.00 and a beta of 2.03. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92.
Omada Health (NASDAQ:OMDA - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The business had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. Sell-side analysts predict that Omada Health, Inc. will post 0.09 EPS for the current year.
Institutional Investors Weigh In On Omada Health
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in Omada Health in the second quarter worth about $48,775,000. SG Americas Securities LLC acquired a new stake in shares of Omada Health during the 1st quarter worth approximately $10,401,000. Jefferies Financial Group Inc. acquired a new stake in shares of Omada Health during the 2nd quarter worth approximately $15,016,000. Madryn Asset Management LP bought a new stake in shares of Omada Health in the 2nd quarter worth approximately $12,814,410. Finally, Walleye Capital LLC bought a new stake in shares of Omada Health in the 2nd quarter worth approximately $11,648,000.
Analyst Ratings Changes
OMDA has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their price target on shares of Omada Health from $26.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, August 14th. BTIG Research restated a "buy" rating and set a $35.00 price objective on shares of Omada Health in a research note on Friday, September 11th. Robert W. Baird increased their target price on Omada Health from $15.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Wall Street Zen lowered Omada Health from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $24.00 price target on shares of Omada Health in a report on Friday, August 7th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.67.
View Our Latest Stock Report on OMDA
Omada Health Company Profile
(
Get Free Report)
Omada Health, Inc is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines connected health devices, digital tools, health coaching and clinical support to help members improve their health and manage conditions such as diabetes, hypertension and musculoskeletal disorders.
The company's services are designed for employers, health plans and other healthcare organizations seeking to support populations with ongoing healthcare needs.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.